{
    "response": "**Overall Treatment Decision:** Yes\u2014treat\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days (or oral equivalent 1 g)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Functionally significant acute relapse (optic neuritis with ataxia) Early steroids shorten time to neurological recovery Low risk when infection is excluded\n\n*   **Treatment:** Proton pump inhibitor and capillary glucose monitoring during steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastroprotection and metabolic safety with high-dose steroids\n\n*   **Treatment:** Physiotherapy and falls-prevention gait training\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Cerebellar ataxia increases fall risk Early rehab improves function\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges) if poor response to steroids\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Second-line for steroid-refractory optic neuritis/cerebellar relapse Initiate if no improvement within 5\u20137 days\n\n*   **Treatment:** Initiate disease-modifying therapy for multiple sclerosis (e.g., ocrelizumab) after confirmation\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Requires diagnostic confirmation and safety screening Prevents future relapses and disability accrual\n\n*   **Treatment:** Long-term immunotherapy for AQP4-positive NMOSD (e.g., rituximab or satralizumab) if confirmed\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Choice depends on antibody status Start after results and counselling\n\n*   **Treatment:** Vitamin D supplementation\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Begin if level is low Potential disease-modifying benefit in demyelination\n\n*   **Treatment:** Vaccination review and avoidance of live vaccines before immunotherapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Immunisation optimisation reduces infection risk with future DMTs\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days (or oral equivalent 1 g)\", \"timing\": \"Start Now\", \"reasons\": [\"Functionally significant acute relapse (optic neuritis with ataxia)\", \"Early steroids shorten time to neurological recovery\", \"Low risk when infection is excluded\"]}, {\"treatment\": \"Proton pump inhibitor and capillary glucose monitoring during steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Gastroprotection and metabolic safety with high-dose steroids\"]}, {\"treatment\": \"Physiotherapy and falls-prevention gait training\", \"timing\": \"Start Now\", \"reasons\": [\"Cerebellar ataxia increases fall risk\", \"Early rehab improves function\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges) if poor response to steroids\", \"timing\": \"Delay\", \"reasons\": [\"Second-line for steroid-refractory optic neuritis/cerebellar relapse\", \"Initiate if no improvement within 5\\u20137 days\"]}, {\"treatment\": \"Initiate disease-modifying therapy for multiple sclerosis (e.g., ocrelizumab) after confirmation\", \"timing\": \"Delay\", \"reasons\": [\"Requires diagnostic confirmation and safety screening\", \"Prevents future relapses and disability accrual\"]}, {\"treatment\": \"Long-term immunotherapy for AQP4-positive NMOSD (e.g., rituximab or satralizumab) if confirmed\", \"timing\": \"Delay\", \"reasons\": [\"Choice depends on antibody status\", \"Start after results and counselling\"]}, {\"treatment\": \"Vitamin D supplementation\", \"timing\": \"Delay\", \"reasons\": [\"Begin if level is low\", \"Potential disease-modifying benefit in demyelination\"]}, {\"treatment\": \"Vaccination review and avoidance of live vaccines before immunotherapy\", \"timing\": \"Delay\", \"reasons\": [\"Immunisation optimisation reduces infection risk with future DMTs\"]}]"
}